Synthesis of Pyranopyrans Related to Diplopyrone and Evaluation as Antibacterials and Herbicides.

Stereoselective syntheses of new pyranopyrans that are related to the natural product diplopyrone, which is a phytotoxin implicated in cork oak decline, have been achieved from carbohydrate starting materials in two approaches that are based on -glycosides as key intermediates. A -alkynyl glycoside prepared by Ferrier rearrangement was used as the precursor to a new pyranopyran alkyne that showed potent antibacterial activity against the common bacterial pathogen that causes enteric septicemia in catfish. The -alkynyl glycoside also showed herbicidal activity.

Synthesis and Biological Evaluation of 6-[(1 R)-1-Hydroxyethyl]-2,4a( R),6( S),8a( R)-tetrahydropyrano-[3,2- b]-pyran-2-one and Structural Analogues of the Putative Structure of Diplopyrone.

The phytotoxin diplopyrone is considered to be the main phytotoxin in a fungus that is responsible for cork oak decline. A carbohydrate-based synthesis of the enantiomer of the structure proposed for diplopyrone has been developed from a commercially available derivative of d-galactose. Key steps in the synthesis are a highly stereoselective pyranose chain-extension based on methyltitanium, preparation of a vinyl glycoside via Isobe C-alkynylation-rearrangement/reduction, and RCM-based pyranopyran construction.

[Venous thrombosis. Experience in treatment, problems and perspectives].

Background: Venous thromboembolic disease is a recurring reason for death, it is often well-known but sometimes misunderstood. The right treatment for this pathology should not follow one approach only, but several strategies with respect to the seriousness and extension of the several clinical pictures. In particular the pharmacological therapy tries to find the balance between risks and benefits.

[Mesoglycan in acute and chronic venous insufficiency of the legs].

Fifty-eight patients with acute and chronic pathology of the lower limbs were treated with daily oral doses of 96 mg of mesoglycan, a drug having antithrombotic and fibrinolytic properties. After a 3-months trial both clinical picture and instrumental parameters were found to be improved.